RU2007121864A - ИМИДАЗО[1,2-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ), КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРОВ GABAA, ИЛИ α1-GABAA, ИЛИ α2-GABAA (ВАРИАНТЫ) - Google Patents
ИМИДАЗО[1,2-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ), КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРОВ GABAA, ИЛИ α1-GABAA, ИЛИ α2-GABAA (ВАРИАНТЫ) Download PDFInfo
- Publication number
- RU2007121864A RU2007121864A RU2007121864/04A RU2007121864A RU2007121864A RU 2007121864 A RU2007121864 A RU 2007121864A RU 2007121864/04 A RU2007121864/04 A RU 2007121864/04A RU 2007121864 A RU2007121864 A RU 2007121864A RU 2007121864 A RU2007121864 A RU 2007121864A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- substituted
- methyl
- para
- tolylimidazo
- Prior art date
Links
- 150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 title claims abstract 4
- 238000000034 method Methods 0.000 title claims 9
- 201000010099 disease Diseases 0.000 title claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 4
- 241000201986 Galenia Species 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- -1 monosubstituted naphthyl Chemical group 0.000 claims abstract 51
- 125000000217 alkyl group Chemical group 0.000 claims abstract 25
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 13
- 239000001257 hydrogen Substances 0.000 claims abstract 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 12
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 11
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 11
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract 10
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims abstract 6
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims abstract 6
- 125000002541 furyl group Chemical group 0.000 claims abstract 6
- 125000002883 imidazolyl group Chemical group 0.000 claims abstract 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims abstract 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims abstract 6
- 125000001624 naphthyl group Chemical group 0.000 claims abstract 6
- 125000004076 pyridyl group Chemical group 0.000 claims abstract 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims abstract 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims abstract 6
- 125000003884 phenylalkyl group Chemical group 0.000 claims abstract 5
- 125000001786 isothiazolyl group Chemical group 0.000 claims abstract 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims abstract 4
- 125000001326 naphthylalkyl group Chemical group 0.000 claims abstract 3
- 125000002971 oxazolyl group Chemical group 0.000 claims abstract 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims abstract 3
- 125000000335 thiazolyl group Chemical group 0.000 claims abstract 3
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
- 125000001041 indolyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
- OTQIEJPVRTUEER-UHFFFAOYSA-N (4-methoxyphenyl) n-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]carbamate Chemical compound C1=CC(OC)=CC=C1OC(=O)NCC1=C(C=2C=CC(C)=CC=2)N=C2N1C=C(C)C=C2 OTQIEJPVRTUEER-UHFFFAOYSA-N 0.000 claims 1
- CESOHFKDGWQUPY-UHFFFAOYSA-N 1-[4-(dimethylamino)phenyl]-3-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]urea Chemical compound C1=CC(N(C)C)=CC=C1NC(=O)NCC1=C(C=2C=CC(C)=CC=2)N=C2N1C=C(C)C=C2 CESOHFKDGWQUPY-UHFFFAOYSA-N 0.000 claims 1
- AKUGRPDTKDFHNE-UHFFFAOYSA-N 1-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]-3-phenylurea Chemical compound C1=CC(C)=CC=C1C1=C(CNC(=O)NC=2C=CC=CC=2)N2C=C(C)C=CC2=N1 AKUGRPDTKDFHNE-UHFFFAOYSA-N 0.000 claims 1
- WGJVDNCXMYRHBP-UHFFFAOYSA-N 1-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]-3-propan-2-ylurea Chemical compound N1=C2C=CC(C)=CN2C(CNC(=O)NC(C)C)=C1C1=CC=C(C)C=C1 WGJVDNCXMYRHBP-UHFFFAOYSA-N 0.000 claims 1
- NOUAWZHYQHTDEJ-UHFFFAOYSA-N 1-cyclohexyl-3-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]urea Chemical compound C1=CC(C)=CC=C1C1=C(CNC(=O)NC2CCCCC2)N2C=C(C)C=CC2=N1 NOUAWZHYQHTDEJ-UHFFFAOYSA-N 0.000 claims 1
- ZWRYJYABHHUFPU-UHFFFAOYSA-N 1-cyclopentyl-3-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]urea Chemical compound C1=CC(C)=CC=C1C1=C(CNC(=O)NC2CCCC2)N2C=C(C)C=CC2=N1 ZWRYJYABHHUFPU-UHFFFAOYSA-N 0.000 claims 1
- DWSPBIIPFKKTAQ-UHFFFAOYSA-N 1-ethyl-3-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]urea Chemical compound N1=C2C=CC(C)=CN2C(CNC(=O)NCC)=C1C1=CC=C(C)C=C1 DWSPBIIPFKKTAQ-UHFFFAOYSA-N 0.000 claims 1
- IMDAQKCLUXUBAO-UHFFFAOYSA-N 2-chloro-n-methyl-n-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]pyridine-4-carboxamide Chemical compound C=1C=NC(Cl)=CC=1C(=O)N(C)CC(N1C=C(C)C=CC1=N1)=C1C1=CC=C(C)C=C1 IMDAQKCLUXUBAO-UHFFFAOYSA-N 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 claims 1
- RDGHSFLKJOYRPN-UHFFFAOYSA-N 5-methyl-n-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]pyrazine-2-carboxamide Chemical compound C1=CC(C)=CC=C1C1=C(CNC(=O)C=2N=CC(C)=NC=2)N2C=C(C)C=CC2=N1 RDGHSFLKJOYRPN-UHFFFAOYSA-N 0.000 claims 1
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010021118 Hypotonia Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- QFXZNEDOFNLHLH-UHFFFAOYSA-N [6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methylcarbamic acid Chemical compound Cc1ccc(cc1)-c1nc2ccc(C)cn2c1CNC(O)=O QFXZNEDOFNLHLH-UHFFFAOYSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 150000001263 acyl chlorides Chemical class 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- LDIKCXZKVGDJNF-UHFFFAOYSA-N benzyl n-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]carbamate Chemical compound C1=CC(C)=CC=C1C1=C(CNC(=O)OCC=2C=CC=CC=2)N2C=C(C)C=CC2=N1 LDIKCXZKVGDJNF-UHFFFAOYSA-N 0.000 claims 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- DAJCGNDSCWPLDH-UHFFFAOYSA-N ethyl n-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]carbamate Chemical compound N1=C2C=CC(C)=CN2C(CNC(=O)OCC)=C1C1=CC=C(C)C=C1 DAJCGNDSCWPLDH-UHFFFAOYSA-N 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 239000012948 isocyanate Substances 0.000 claims 1
- 150000002513 isocyanates Chemical class 0.000 claims 1
- RNFARXKWDQJNLG-UHFFFAOYSA-N methyl n-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]carbamate Chemical compound N1=C2C=CC(C)=CN2C(CNC(=O)OC)=C1C1=CC=C(C)C=C1 RNFARXKWDQJNLG-UHFFFAOYSA-N 0.000 claims 1
- 230000036640 muscle relaxation Effects 0.000 claims 1
- AWRLGWNAYODVRB-UHFFFAOYSA-N n-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]-2-thiophen-2-ylacetamide Chemical compound C1=CC(C)=CC=C1C1=C(CNC(=O)CC=2SC=CC=2)N2C=C(C)C=CC2=N1 AWRLGWNAYODVRB-UHFFFAOYSA-N 0.000 claims 1
- HCRNXOBUKNXIHO-UHFFFAOYSA-N n-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]-5-nitrofuran-2-carboxamide Chemical compound C1=CC(C)=CC=C1C1=C(CNC(=O)C=2OC(=CC=2)[N+]([O-])=O)N2C=C(C)C=CC2=N1 HCRNXOBUKNXIHO-UHFFFAOYSA-N 0.000 claims 1
- GKTQXWFKFQDRAW-UHFFFAOYSA-N n-methyl-n-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]-5-nitrofuran-2-carboxamide Chemical compound C=1C=C([N+]([O-])=O)OC=1C(=O)N(C)CC(N1C=C(C)C=CC1=N1)=C1C1=CC=C(C)C=C1 GKTQXWFKFQDRAW-UHFFFAOYSA-N 0.000 claims 1
- YSOFNHDSQMGJHU-UHFFFAOYSA-N n-methyl-n-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]thiophene-2-carboxamide Chemical compound C=1C=CSC=1C(=O)N(C)CC(N1C=C(C)C=CC1=N1)=C1C1=CC=C(C)C=C1 YSOFNHDSQMGJHU-UHFFFAOYSA-N 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- JWMKFHLKLVRHOT-UHFFFAOYSA-N phenyl n-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]carbamate Chemical compound C1=CC(C)=CC=C1C1=C(CNC(=O)OC=2C=CC=CC=2)N2C=C(C)C=CC2=N1 JWMKFHLKLVRHOT-UHFFFAOYSA-N 0.000 claims 1
- GYPIEUFQDFPIIT-UHFFFAOYSA-N prop-2-ynyl n-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]carbamate Chemical compound C1=CC(C)=CC=C1C1=C(CNC(=O)OCC#C)N2C=C(C)C=CC2=N1 GYPIEUFQDFPIIT-UHFFFAOYSA-N 0.000 claims 1
- GNJXXMQEARZTCP-UHFFFAOYSA-N propan-2-yl n-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]carbamate Chemical compound N1=C2C=CC(C)=CN2C(CNC(=O)OC(C)C)=C1C1=CC=C(C)C=C1 GNJXXMQEARZTCP-UHFFFAOYSA-N 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04105698 | 2004-11-11 | ||
| EP04105698.7 | 2004-11-11 | ||
| PCT/EP2005/055753 WO2006051063A1 (en) | 2004-11-11 | 2005-11-04 | Imidazo[1,2-a]pyridine compounds, compositions, uses and methods related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007121864A true RU2007121864A (ru) | 2008-12-20 |
Family
ID=34929843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007121864/04A RU2007121864A (ru) | 2004-11-11 | 2005-11-04 | ИМИДАЗО[1,2-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ), КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРОВ GABAA, ИЛИ α1-GABAA, ИЛИ α2-GABAA (ВАРИАНТЫ) |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20080200473A1 (https=) |
| EP (1) | EP1814880B1 (https=) |
| JP (1) | JP2008519805A (https=) |
| KR (1) | KR20070084026A (https=) |
| CN (1) | CN101065377B (https=) |
| AR (1) | AR051626A1 (https=) |
| AT (1) | ATE421962T1 (https=) |
| AU (1) | AU2005303811A1 (https=) |
| BR (1) | BRPI0517796A (https=) |
| CA (1) | CA2585315A1 (https=) |
| DE (1) | DE602005012598D1 (https=) |
| DK (1) | DK1814880T3 (https=) |
| ES (1) | ES2321858T3 (https=) |
| IL (1) | IL182963A0 (https=) |
| MX (1) | MX2007005611A (https=) |
| NO (1) | NO20072831L (https=) |
| PA (1) | PA8652101A1 (https=) |
| PE (1) | PE20060967A1 (https=) |
| PL (1) | PL1814880T3 (https=) |
| PT (1) | PT1814880E (https=) |
| RU (1) | RU2007121864A (https=) |
| TW (1) | TWI357412B (https=) |
| UY (1) | UY29204A1 (https=) |
| WO (1) | WO2006051063A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2477604A1 (en) | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
| WO2006084033A1 (en) | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| EP1845098A1 (en) * | 2006-03-29 | 2007-10-17 | Ferrer Internacional, S.A. | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands |
| AU2007267183B2 (en) * | 2006-05-31 | 2011-10-20 | F. Hoffmann-La Roche Ag | Aryl-4-ethynyl-isoxazole derivatives |
| CN101528226B (zh) * | 2006-08-24 | 2012-01-11 | 澳大利亚核科学技术组织 | 靶向外周苯二氮卓受体的氟化配体 |
| JP5607025B2 (ja) | 2008-04-21 | 2014-10-15 | シグナム バイオサイエンシーズ， インコーポレイテッド | 化合物、組成物およびそれらを作製する方法 |
| CA2724842A1 (en) * | 2008-05-19 | 2009-11-26 | Sunovion Pharmaceuticals Inc. | Imidazo[1,2-a]pyridine compounds |
| US10478438B2 (en) | 2008-10-16 | 2019-11-19 | David Reed Helton | Treatment of organophosphate exposure with ocinaplon |
| US20120010188A1 (en) * | 2008-12-04 | 2012-01-12 | Promimagen Ltd. | Imidazopyridine Compounds |
| EP2496578A4 (en) | 2009-11-05 | 2013-08-21 | Univ Notre Dame Du Lac | IMIDAZO [1,2-A] PYRIDINE COMPOUNDS, THEIR SYNTHESIS AND METHODS OF USE THEREOF |
| TW201225957A (en) | 2010-09-17 | 2012-07-01 | Taisho Pharmaceutical Co Ltd | Glycine transporter inhibitor |
| KR20180053386A (ko) | 2015-09-17 | 2018-05-21 | 마빈 제이. 밀러 | 마이코박테리아 감염에 대해 유용한 벤질 아민-함유 헤테로사이클릭 화합물 및 조성물 |
| WO2017087885A1 (en) | 2015-11-19 | 2017-05-26 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers |
| CN106906486B (zh) * | 2017-02-22 | 2018-12-11 | 华南理工大学 | 3-溴-2-苯基-咪唑并[1,2-α]吡啶类衍生物的电化学合成方法 |
| WO2019152437A1 (en) | 2018-01-30 | 2019-08-08 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020081588A1 (en) | 2018-10-17 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Swi/snf family chromatin remodeling complexes and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020160100A1 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US20230121497A1 (en) * | 2020-01-29 | 2023-04-20 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CA3167275A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| JP2024509268A (ja) | 2021-03-09 | 2024-02-29 | フォグホーン セラピューティクス インコーポレイテッド | 結晶形、それらを含有する組成物、及びそれらの使用方法 |
| CN118515663A (zh) * | 2023-04-24 | 2024-08-20 | 上海赛默罗生物科技有限公司 | 咪唑并吡啶或咪唑并吡嗪类化合物、其制备方法、药物组合物和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2568880B1 (fr) * | 1984-08-07 | 1986-12-12 | Synthelabo | Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique |
| FR2593818B1 (fr) * | 1986-02-05 | 1988-04-29 | Synthelabo | Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique |
| FR2593181B1 (fr) * | 1986-01-22 | 1988-04-01 | Synthelabo | Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique |
| ATE62687T1 (de) * | 1986-01-22 | 1991-05-15 | Synthelabo | Acylaminomethylimidazo(1,2-a>pyrimidinderivate, ihre herstellung und therapeutische verwendung. |
| US20040204443A1 (en) * | 2003-01-27 | 2004-10-14 | Arthur Zaks | Method for inducing pain relief using imidazo[1,2-a]pyridine derivatives |
-
2005
- 2005-11-04 DK DK05808135T patent/DK1814880T3/da active
- 2005-11-04 US US11/667,494 patent/US20080200473A1/en not_active Abandoned
- 2005-11-04 KR KR1020077010318A patent/KR20070084026A/ko not_active Ceased
- 2005-11-04 AT AT05808135T patent/ATE421962T1/de active
- 2005-11-04 ES ES05808135T patent/ES2321858T3/es not_active Expired - Lifetime
- 2005-11-04 MX MX2007005611A patent/MX2007005611A/es active IP Right Grant
- 2005-11-04 DE DE602005012598T patent/DE602005012598D1/de not_active Expired - Lifetime
- 2005-11-04 AU AU2005303811A patent/AU2005303811A1/en not_active Abandoned
- 2005-11-04 BR BRPI0517796-0A patent/BRPI0517796A/pt not_active IP Right Cessation
- 2005-11-04 PT PT05808135T patent/PT1814880E/pt unknown
- 2005-11-04 WO PCT/EP2005/055753 patent/WO2006051063A1/en not_active Ceased
- 2005-11-04 EP EP05808135A patent/EP1814880B1/en not_active Expired - Lifetime
- 2005-11-04 JP JP2007540634A patent/JP2008519805A/ja active Pending
- 2005-11-04 CN CN2005800386913A patent/CN101065377B/zh not_active Expired - Fee Related
- 2005-11-04 CA CA002585315A patent/CA2585315A1/en not_active Abandoned
- 2005-11-04 PL PL05808135T patent/PL1814880T3/pl unknown
- 2005-11-04 RU RU2007121864/04A patent/RU2007121864A/ru not_active Application Discontinuation
- 2005-11-07 PE PE2005001302A patent/PE20060967A1/es not_active Application Discontinuation
- 2005-11-08 PA PA20058652101A patent/PA8652101A1/es unknown
- 2005-11-08 TW TW094139042A patent/TWI357412B/zh not_active IP Right Cessation
- 2005-11-09 AR ARP050104693A patent/AR051626A1/es not_active Application Discontinuation
- 2005-11-10 UY UY29204A patent/UY29204A1/es not_active Application Discontinuation
-
2007
- 2007-05-03 IL IL182963A patent/IL182963A0/en unknown
- 2007-06-04 NO NO20072831A patent/NO20072831L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1814880A1 (en) | 2007-08-08 |
| AR051626A1 (es) | 2007-01-24 |
| CN101065377B (zh) | 2011-07-27 |
| PA8652101A1 (es) | 2006-10-13 |
| UY29204A1 (es) | 2006-01-31 |
| PE20060967A1 (es) | 2006-09-20 |
| CA2585315A1 (en) | 2006-05-18 |
| MX2007005611A (es) | 2007-07-11 |
| EP1814880B1 (en) | 2009-01-28 |
| DE602005012598D1 (de) | 2009-03-19 |
| TW200624432A (en) | 2006-07-16 |
| PL1814880T3 (pl) | 2009-07-31 |
| ATE421962T1 (de) | 2009-02-15 |
| IL182963A0 (en) | 2007-08-19 |
| WO2006051063A1 (en) | 2006-05-18 |
| BRPI0517796A (pt) | 2008-10-28 |
| PT1814880E (pt) | 2009-04-23 |
| TWI357412B (en) | 2012-02-01 |
| AU2005303811A1 (en) | 2006-05-18 |
| CN101065377A (zh) | 2007-10-31 |
| ES2321858T3 (es) | 2009-06-12 |
| US20080200473A1 (en) | 2008-08-21 |
| KR20070084026A (ko) | 2007-08-24 |
| JP2008519805A (ja) | 2008-06-12 |
| DK1814880T3 (da) | 2009-05-18 |
| NO20072831L (no) | 2007-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007121864A (ru) | ИМИДАЗО[1,2-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ), КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРОВ GABAA, ИЛИ α1-GABAA, ИЛИ α2-GABAA (ВАРИАНТЫ) | |
| JP2008519805A5 (https=) | ||
| JP5412429B2 (ja) | 抗細菌性アミド及びスルホンアミド置換複素環式尿素化合物 | |
| JP5182088B2 (ja) | アゾールカルボキサミド誘導体 | |
| JP7606537B2 (ja) | 神経筋疾患の処置のためのピリダジノン化合物 | |
| CA2565813A1 (en) | Substituted methyl aryl or heteroaryl amide compounds | |
| CA2407428A1 (en) | Hydantoin-containing glucokinase activators | |
| US12195432B2 (en) | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | |
| CA2436935A1 (en) | Serine protease inhibitors | |
| KR20150015031A (ko) | 고아 핵 수용체 ror[감마]의 조절제로서의 카복사미드 또는 설폰아미드가 치환된 티아졸 및 관련된 유도체 | |
| RU2010119645A (ru) | Замещенные гетероциклом пиперазинодигидротиенопиримидины | |
| HRP20120656T1 (hr) | Derivati indazolil amida za liječenje poremećaja posredovanih glukokortikoidnim receptorom | |
| RU2011116232A (ru) | Пиразолопиридиновые производные как ингибиторы надфн-оксидазы | |
| RU2007101685A (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения | |
| RU2005125204A (ru) | Соединения конденсированного фурана | |
| JP7376358B2 (ja) | オピオイド受容体調節因子としての多環式アミン | |
| JP2005514432A5 (https=) | ||
| EP4433473A1 (en) | Pyridazinone compounds and uses thereof | |
| KR20080034436A (ko) | 암 치료에 사용되는 티아졸 유도체 및 유사체 | |
| CA2470427A1 (en) | Compositions and methods for treating heart failure | |
| EA012260B1 (ru) | ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ МЕТИЛЕНАМИДА В КАЧЕСТВЕ МОДУЛЯТОРОВ ПРОТЕИНТИРОЗИНФОСФАТАЗ (PTPs) | |
| DE102004023635A1 (de) | Heteroarylsubstituierte Cyclohexyl-1,4-diamin-Derivate | |
| JP2008513497A5 (https=) | ||
| CA2532437A1 (en) | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | |
| RU2011108968A (ru) | Производные пиридина в качестве ингибиторов рецепторов фактора роста эндотелия сосудов 2 подтипа (vegfr-2) и протеинтирозинкиназы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100721 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20110711 |
|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20120827 |